PBC Ireland - Publications

Khan NA, et al. 2026. Safety profile of elafibranor versus placebo in primary biliary cholangitis: A systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. Medicine (Baltimore) (Oct 2026)

Wilder JM, et al. 2026. Sex and racial disparities in clinical outcomes and health resource use among patients with primary biliary cholangitis in the United States. Hepatol Commun (Oct 2026)

Khurram NA, et al. 2026. Histopathologic and immunophenotypic features distinguishing recurrent primary biliary cholangitis from liver allograft rejection. Ann Diagn Pathol (Sep 2026)

Levy C, et al. 2026. EP547 (MRGPRX4 inverse agonist) for cholestatic pruritus due to primary biliary cholangitis or primary sclerosing cholangitis: Results from the phase 2 randomized, placebo-controlled PACIFIC study. Ann Hepatol (Sep 2026)

Choi YJ, et al. 2026. Serum Metabolomic Profiling Reveals Potential Mechanisms and Biomarkers of Seladelpar Treatment in Patients With Primary Biliary Cholangitis. PPAR Res (2026)

Weijsters GHX, et al. 2026. Extrahepatic Autoimmune Disease in People With Primary Biliary Cholangitis: Nationwide Occurrence and Relation to Outcome. Clin Gastroenterol Hepatol (Sep 2026)

Gerussi A, et al. 2026. A Genetic Risk Variant Associated With the Risk of Primary Biliary Cholangitis Is Inherited From Neanderthals. Liver Int (Oct 2026)

Kleinertz A, et al. 2026. Machine-perfused Donation After Circulatory Death Grafts Improve Access to Liver Transplant for Primary Biliary Cholangitis Patients. Transplant Direct (Oct 2026)

Zou T, et al. 2026. Causal effects of circulating cathepsins on cholecystitis, cholelithiasis, primary biliary cholangitis, primary sclerosing cholangitis, acute pancreatitis, and chronic pancreatitis: A Mendelian randomization study. Medicine (Baltimore) (Sep 2026)

Xiong J, et al. 2026. Immune cell remodelling and the peribiliary immune niche in primary biliary cholangitis: from initiation to chronicity. eGastroenterology (2026)

Jin Y, et al. 2026. Assessment of a chemiluminescence immunoassay for antimitochondrial antibody subtype M2 in the diagnosis of primary biliary cholangitis. Lab Med (Aug 2026)

Khurram NA, et al. 2026. Impact of ursodeoxycholic acid on histologic and immunophenotypic features in primary biliary cholangitis. Pathol Res Pract (Sep 2026)

Hüsing P, et al. 2026. Cognitive-Affective Predictors of Exertion-Related Fatigue in Primary Biliary Cholangitis: An Experimental Substudy of the SOMA.LIV Project. Psychol Res Behav Manag (2026)

Liu Y, et al. 2026. Expression and clinical characteristics of CD161 in primary biliary cholangitis. Immunol Lett (Sep 2026)

Sandhu S, Goel A. 2026. Advances in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Semin Liver Dis (Jun 2026)

Ando Y, et al. 2026. Porto-Sinusoidal Vascular Disorder-Spectrum Portal Venopathy as a Structural Substrate for Portal Hypertension in Anti-Centromere Antibody-Positive Primary Biliary Cholangitis. Pathol Int (Sep 2026)

Pei X, et al. 2026. Label-Free Urinary Proteomics Uncovers Immune-Related Non-Invasive Biomarkers for Primary Biliary Cholangitis. Int J Mol Sci (Aug 2026)

Méndez-Sánchez N, et al. 2026. The increasing burden of primary biliary cholangitis-related cirrhosis in Mexico: Evidence from a contemporary multicenter cohort. Rev Gastroenterol Mex (Engl Ed) (Sep 2026)

Cançado GGL, et al. 2026. Temporal trends in the epidemiology of primary biliary cholangitis in the public healthcare system of Brazil: a large population-based study. Lancet Reg Health Am (Nov 2026)

Gaur P, et al. 2026. Associations of primary biliary cholangitis and primary sclerosing cholangitis with adverse pregnancy outcomes: a propensity score-matched analysis of a U.S. multicenter cohort. Am J Obstet Gynecol MFM (Sep 2026)

Nguyen QT, et al. 2026. Sex disparities in primary biliary cholangitis: insights from a Japanese multicentre cohort. Med Mol Morphol (Sep 2026)

Halilbasic E, et al. 2026. Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis. Wien Klin Wochenschr (Sep 2026)

Levy C, et al. 2026. Unravelling the Itch: Cross-Sectional Analysis of Pruritus Patterns in the PicnicHealth Primary Biliary Cholangitis Registry. Liver Int (Oct 2026)

Marenco-Flores A, et al. 2026. Sleep disorders in primary biliary cholangitis: A prospective analysis of clinical and patient-reported outcomes. Ann Hepatol (Sep 2026)

Cheng H, et al. 2026. Temporal sequence in chronic kidney disease risk assessment in primary biliary cholangitis. J Gastroenterol (Sep 2026)

Juran BD, et al. 2026. Bile Acid Profiles Define Disease-Specific Cholestatic States in Primary Sclerosing and Primary Biliary Cholangitis. Gastro Hep Adv (2026)

Sanai FM, et al. 2026. Primary Biliary Cholangitis in the Middle East: A Review of Current Challenges and Treatment Approaches. Cureus (Jul 2026)

Kowdley KV, et al. 2026. Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial. J Hepatol (Aug 2026)

Younossi ZM, et al. 2026. Liver transplantation for cholestatic liver diseases: Trends in primary biliary cholangitis and primary sclerosing cholangitis in the US and Europe over two decades. Liver Transpl (Aug 2026)

Pan T, et al. 2026. Retraction notice to "the molecular structure of SHISA5 protein and its novel role in primary biliary cholangitis: From single-cell RNA sequencing to biomarkers" [Int. J. Biol. Macromol. 296 (2025) 139775]. Int J Biol Macromol (Aug 2026)

. 2026. Elafibranor for primary biliary cholangitis. Aust Prescr (Aug 2026)

Liu J, et al. 2026. Primary Biliary Cholangitis-Associated Granulomatous Interstitial Lung Disease: Pulmonary Epithelial-Interface Injury Supporting the Concept of Generalized Autoimmune Epithelitis. Pathol Int (Aug 2026)

Zahra M, et al. 2026. Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial. J Gastroenterol Hepatol (Oct 2026)

Fan Z, et al. 2026. Liver-kidney crosstalk in primary biliary cholangitis: insights into the mechanisms of renal involvement. Front Immunol (2026)

Feng J, et al. 2026. Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PLoS One (2026)

Williams EE, Vuppalanchi R. 2026. An itch finally addressed: linerixibat and the promise of targeted antipruritic therapy in primary biliary cholangitis. Transl Gastroenterol Hepatol (2026)

Shamseddine N, et al. 2026. Real-world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the United States. J Comp Eff Res (Sep 2026)

Kumar S, et al. 2026. Burden of fatigue or pruritus in patients with primary biliary cholangitis: a United States matched case-control study. J Comp Eff Res (Sep 2026)

Dou Y, Liu J. 2026. Development and evaluation of explainable machine learning models for predicting prognosis in patients with primary biliary cholangitis. Front Mol Biosci (2026)

Hitomi Y, et al. 2026. rs57494551 increases CXCR5 expression and IgM CXCR5 B-cell infiltration in the portal area of primary biliary cholangitis. J Gastroenterol (Aug 2026)

Strasser SI, et al. 2026. Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective. J Gastroenterol Hepatol (Sep 2026)

Yoshimura K, et al. 2026. Indoleamine 2,3-Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis. Hepatol Res (Aug 2026)

Zhu L, et al. 2026. Primary Biliary Cholangitis Presenting with Low Back Pain and Complicated by Immune-Mediated Necrotizing Myositis: A Case Report. Eur J Rheumatol (Apr 2026)

Vallejo Rico CF, et al. 2026. Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome With Limited Systemic Sclerosis. Cureus (Jul 2026)

He S, et al. 2026. Clinical applications of anti-centromere antibody in primary biliary cholangitis. Clin Res Hepatol Gastroenterol (Jul 2026)

Kasturi S, et al. 2026. A hepatic enigma: Pediatric presentation of primary biliary cholangitis. JPGN Rep (Jul 2026)

Gohar A, et al. 2026. Overlap of Primary Biliary Cholangitis and Systemic Sclerosis: A Case of Reynolds Syndrome. Clin Case Rep (Aug 2026)

. 2026. AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update. Dig Liver Dis (Sep 2026)

Bantel H, et al. 2026. Characterization of a Northern German Primary Biliary Cholangitis Cohort. Z Gastroenterol (Jul 2026)

Sirirattanakorn S, et al. 2026. Overall Survival and Treatment Outcomes in Patients With Primary Biliary Cholangitis: A 10-Year Single-Center Retrospective Cohort Study. J Clin Exp Hepatol (2026)

Batıbay E, et al. 2026. Pregnancy in Primary Biliary Cholangitis: A Single-Center Experience Emphasizing the Need for Postpartum Monitoring. Turk J Gastroenterol (Jul 2026)

Ronconi G, et al. 2026. Burden of primary biliary cholangitis on the Italian National Health Service: retrospective analysis from an administrative database. Glob Reg Health Technol Assess (2026)

Wong YJ, et al. 2026. Recurrence of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis after Liver Transplantation: Current Evidence and Clinical Implications. Clin Liver Dis (Aug 2026)

Bolis F, Carbone M. 2026. Primary Biliary Cholangitis. Clin Liver Dis (Aug 2026)

Violatto MB, et al. 2026. Steroid-loaded Avidin-Nucleic-Acid-Nano-Assemblies reduce hepatic fibrosis modulating Kupffer cells in primary biliary cholangitis. Biomed Pharmacother (Sep 2026)

Zhao H, et al. 2026. A Dual Time Window-driven Strategy to Optimize Primary Biliary Cholangitis Treatment via Alkaline Phosphatase Normalization. J Clin Transl Hepatol (Jun 2026)

Suchowiecki K, Wu GY. 2026. Antimitochondrial Antibody Measurements in the Diagnosis of Antimitochondrial Antibody-negative and Alkaline Phosphatase-positive Primary Biliary Cholangitis: An Update and Review. J Clin Transl Hepatol (Jun 2026)

Takeuchi A, et al. 2026. Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow-Up. Hepatol Res (Jul 2026)

Khamis F, et al. 2026. Suboptimal response to ursodeoxycholic acid among patients with primary biliary cholangitis and fenofibrate as add-on therapy: a single-centre retrospective study. Singapore Med J (Jul 2026)

Moriya K, et al. 2026. Glucosyl Hesperidin Benefits in Primary Biliary Cholangitis: A Multicenter, Open-Label, Randomized Controlled Study. Clin Transl Gastroenterol (Sep 2026)

Assis DN. 2026. Delphi consensus in primary biliary cholangitis: Collective introspection to set a path forward. J Hepatol (Sep 2026)

Tanigawa R, et al. 2026. Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis. Hepatol Res (Jul 2026)

Syed H, et al. 2026. Machine Learning Predicts Treatment Response and Prognostic Pathways From Whole-Blood Transcriptome in Primary Biliary Cholangitis. Liver Int (Aug 2026)

Bowlus CL, et al. 2026. Long-Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long-Term Safety Extension. Aliment Pharmacol Ther (Oct 2026)

Chen Z, et al. 2026. Integrative analysis of genetic and cellular interactions connecting inflammatory bowel disease and primary biliary cholangitis. Clin Res Hepatol Gastroenterol (Aug 2026)

Aronsohn F, Poniachik J. 2026. [Hepatic Overlap Syndrome: Primary Sclerosing Cholangitis and Primary Biliary Cholangitis. Case Review]. Rev Med Chil (Apr 2026)

Juskova I, et al. 2026. Primary biliary cholangitis: Beyond classical histopathology - diagnostic challenges in native and transplanted livers. Ann Diagn Pathol (Dec 2026)

Levy C, et al. 2026. Qualitative Evaluation of Fatigue and Pruritus Among Patients with Primary Biliary Cholangitis. Adv Ther (Oct 2026)

Su M, et al. 2026. Neutrophil extracellular traps drive cholangiocyte injury via ZNF709-TP53-MDM2 pathway in primary biliary cholangitis. Hepatol Int (Jul 2026)

He C, et al. 2026. Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial. J Gastroenterol Hepatol (Aug 2026)

Tan JJ, et al. 2026. Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic-Dysfunction Associated Steatotic Liver Disease. Liver Int (Aug 2026)

Mirowski K, et al. 2026. Environmental shaping of tolerance failure in autoimmune liver diseases: a phenotype-specific framework with primary biliary cholangitis as the strongest model. J Transl Autoimmun (Dec 2026)

Alamgir M, et al. 2026. A Review of Therapies for Primary Biliary Cholangitis. Gastroenterol Hepatol (N Y) (Jul 2026)

Ran Y, et al. 2026. [Dietary serine supplementation inhibits the hepatic macrophage AKT/mTOR pathway and improves primary biliary cholangitis]. Zhonghua Gan Zang Bing Za Zhi (Jun 2026)

Crittenden DB, Hirschfield GM. 2026. Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence. Aliment Pharmacol Ther (Jun 2026)

Qianlang R, et al. 2026. Gut microbiota alterations in primary biliary cholangitis: a systematic review and meta-analysis. Front Microbiol (2026)

Liu T, et al. 2026. Monocyte-Derived Macrophage Ferroptosis Amplifies Cholangitis in Primary Biliary Cholangitis via a Calpain/ACSL4 Axis. Biomedicines (May 2026)

Ortega-Torres A, et al. 2026. Primary biliary cholangitis mortality in Europe: a temporal and spatial view across the period 2002-2022. BMC Public Health (Jun 2026)

Abadi-Ron VE, et al. 2026. Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review. Turk J Gastroenterol (Jun 2026)

Njei B, Sidney Kanmounye U. 2026. An Explainable AI Framework for Continuous Monitoring, Risk Stratification, and Clinical Decision Support in Primary Biliary Cholangitis: Protocol for a Multiphase Development and Validation Study. JMIR Res Protoc (Jun 2026)

Zheng M, et al. 2026. Prognostic nutritional index as a predictor of ursodeoxycholic acid response in primary biliary cholangitis: a retrospective study. BMC Gastroenterol (Jun 2026)

Sousa JM, et al. 2026. Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis. J Gastroenterol (Sep 2026)

Rogalska M, et al. 2026. Circulating matrix metalloproteinase profile in early-stage primary biliary cholangitis. Sci Rep (Jun 2026)

Li S, et al. 2026. Letter: A Histology-Defined Triple-Negative Phenotype of Primary Biliary Cholangitis. Aliment Pharmacol Ther (Sep 2026)

Yan Y, et al. 2026. Folate deficiency correlates with severity of primary biliary cholangitis via modulating key regulatory genes. Front Nutr (2026)

Yamashita Y, et al. 2026. Baseline and Longitudinal Liver Stiffness Measurement Predict Outcomes in Primary Biliary Cholangitis: A Multicenter Study. Hepatol Res (Jun 2026)

Awan MA. 2026. AMA-Positive Cholestasis in Celiac Disease: Why Primary Biliary Cholangitis Should Not Be Excluded by Biopsy Alone. Clin Case Rep (Jun 2026)

Kanda T, et al. 2026. Linerixibat reduces cholestatic pruritus in patients with primary biliary cholangitis. Transl Gastroenterol Hepatol (2026)

Palomer X, et al. 2026. The emerging role of PPARs in primary biliary cholangitis. Trends Mol Med (Jun 2026)

Franke A, et al. 2026. Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-world setting. Ann Hepatol (Jun 2026)

Hayashi M, et al. 2026. Utility of pretreatment GLOBE score as a non-invasive prognostic tool in primary biliary cholangitis. Immunol Med (Jun 2026)

Hanatani T, et al. 2026. [A case of primary biliary cholangitis whose pathology changed during autoimmune hepatitis]. Nihon Shokakibyo Gakkai Zasshi (2026)

Werner E, et al. 2026. Bezafibrate for primary biliary cholangitis: A number needed to treat analysis. JHEP Rep (Aug 2026)

Huang M, et al. 2026. Glasgow Prognostic Score Predicts Hepatic Recompensation in Decompensated Primary Biliary Cholangitis: A Multicenter Cohort Study. J Inflamm Res (2026)

Zhang J, et al. 2026. Comparative efficacy and safety of ursodeoxycholic acid, fibrates, and combination therapy in primary biliary cholangitis: an umbrella meta-analysis of meta-analyses. Front Pharmacol (2026)

Nursoy M, et al. 2026. Systemic sclerosis and primary biliary cholangitis: a systematic review of case-control studies comparing isolated and overlapping disease phenotypes. J Scleroderma Relat Disord (2026)

Zhang J, et al. 2026. High Prevalence of Sarcopenia in Noncirrhotic Women With Primary Biliary Cholangitis: A Comparative Study of Clinical Characteristics and Risk Factors. Gastroenterol Res Pract (2026)

Bian S, et al. 2026. A segregating PTK2B variant in a primary biliary cholangitis (PBC) family induces PBC-like autoimmune features in knock-in mice. Cell Biosci (Jun 2026)

Del Barrio M, et al. 2026. Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes. Liver Int (Jul 2026)

(Facebook is for Irish PBC patients only)

Recent News

URSO Calculator

Sep 13th, 2026
PBC Ireland Marks International PBC Awareness Day

Sep 12th, 2026
PBC Ireland reaches 160 members

Aug 20th, 2026
PBC PBC Ireland Patient Registry Reaches 72 Participants

Aug 3rd, 2026
PBC Ireland Research Accepted for The Liver Meeting 2026

Mar 27th, 2026
PBC Ireland joins the PBC PAG with United Liver

Mar 17th, 2026
PBC Ireland partners with C-PATH

May 8th, 2025
PBC Ireland Launched!

Publications(100 publications from PubMed)

Recent News

Publications
(100 publications from PubMed)